Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss called Wegovy. If everything goes according to plan, the generic drug manufacturer will soon get regulatory approval for its two copies of Novo Nordisk's diabetes and weight loss medicines, potentially raking in billions in the process.
It's a no-brainer that such a big development could excite investors and send Viatris' stock climbing. But there are some complications involved and the issue is far from decided. On top of that, success in the market might be harder to come by than it seems.
Is Viatris stock a buy based on the expectations of this play succeeding, or is it better to invest in something else?
Source Fool.com
Viatris Inc. Stock
Currently there is a rather positive sentiment for Viatris Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 12 € there is a positive potential of 23.08% for Viatris Inc. compared to the current price of 9.75 €.
Comments
The comment is under review
